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Abstract
Background: Epigenetic changes are emerging as one of the most important events in carcinogenesis. Two alterations in
the pattern of DNA methylation in breast cancer (BC) have been previously reported; active estrogen receptor-a (ER-a) is
associated with decreased methylation of ER-a target (ERT) genes, and polycomb group target (PCGT) genes are more likely
than other genes to have promoter DNA hypermethylation in cancer. However, whether DNA methylation in normal
unrelated cells is associated with BC risk and whether these imprints can be related to factors which can be modified by the
environment, is unclear.
Methodology/Principal Findings: Using quantitative methylation analysis in a case-control study (n = 1,083) we found that
DNA methylation of peripheral blood cell DNA provides good prediction of BC risk. We also report that invasive ductal and
invasive lobular BC is characterized by two different sets of genes, the latter particular by genes involved in the
differentiation of the mesenchyme (PITX2, TITF1, GDNF and MYOD1). Finally we demonstrate that only ERT genes predict ER
positive BC; lack of peripheral blood cell DNA methylation of ZNF217 predicted BC independent of age and family history
(odds ratio 1.49; 95% confidence interval 1.12–1.97; P = 0.006) and was associated with ER-a bioactivity in the corresponding
serum.
Conclusion/Significance: This first large-scale epigenotyping study demonstrates that DNA methylation may serve as a link
between the environment and the genome. Factors that can be modulated by the environment (like estrogens) leave an
imprint in the DNA of cells that are unrelated to the target organ and indicate the predisposition to develop a cancer.
Further research will need to demonstrate whether DNA methylation profiles will be able to serve as a new tool to predict
the risk of developing chronic diseases with sufficient accuracy to guide preventive measures.
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Introduction
Each year, more than 1.15 million new cases of breast cancer
are diagnosed worldwide [1]. Currently the Gail model, based on
epidemiological risk factors, is the best we have of predicting
overall risk of invasive breast cancer and the concordance statistics
for correctly classifying women with respect to this outcome is 58–
59% [2].
Epigenetic changes, in particular DNA methylation, are
emerging as one of the most important events in carcinogenesis
[3–6]. Recently, an increasing body of evidence from animal
studies demonstrated that environmental factors can result in
epigenetic modifications and subsequent changes in the risk of
developing disease [7,8]. There is preliminary evidence from small
studies that peripheral blood cell DNA contains epigenetic
information, which is a valuable predictive marker of an
individual’s risk of developing cancer [9,10,11]. Only the largest
of these studies, involving 172 individuals and analyzing one locus,
demonstrated that epigenetic alterations are able to predict the risk
of colorectal cancer independently of family history [9].
We have undertaken a large scale study to test the hypothesis
that methylation in peripheral blood cell DNA may be a predictor
of breast cancer risk. Recently, two alterations in the pattern of
DNA methylation in breast cancer have been described. First,
active estrogen receptor-a (ER-a), which reflects breast cancer risk,
is associated with decreased methylation of ER-a target genes
(ERT) [12,13]. Second, polycomb group target genes (PCGT),
which play a key role in stem cell biology, are more likely to have
promoter DNA hypermethylation in cancer than other genes
[14,15,16]. These observations led to our hypothesis that the
pattern of peripheral blood cell DNA methylation of ERT genes
and PCGT genes is an important predictor of breast cancer risk.
Based on our previous data we hypothesized that as a function of
time and dose, cumulative estrogen exposure during lifetime leaves
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an epigenetic signature in peripheral white blood cell DNA
(depending on a woman’s genetic and lifestyle background), which
is associated with a postmenopausal risk to develop breast cancer.
Physiologically, aging and decrease of estrogens in the postmeno-
pause may lead to methylation of ERT genes. However, lack of
methylation may be an indicator for a long-term high estrogen
exposure, thus the expectation would be that ERT genes have a
lower frequency of methylation in peripheral blood cell DNA of
women with breast cancer compared to controls. Furthermore,
embryonic stem cells rely on polycomb group proteins to
reversibly repress genes required for differentiation. We recently
reported that stem cell polycomb group targets are up to 12-fold
more likely to have cancer-specific promoter DNA hypermethyla-
tion [14], supporting a stem cell origin of cancer where reversible
gene expression is replaced by permanent silencing, locking the
cell into a perpetual state of self-renewal that predisposes to
subsequent malignant transformation. Based on this, our expec-
tation would be that PCGT genes have a higher frequency of
methylation in peripheral blood cell DNA of women with breast
cancer compared to controls.
In this study we have demonstrated that methylation in
peripheral blood cell DNA is related to breast cancer risk. This
observation opens opportunities for progress in risk assessment and
prevention of breast cancer and is a model for investigation in
other chronic diseases.
Results and Discussion
In order to test our hypothesis that peripheral blood cell DNA
methylation is predictor of breast cancer risk, we took a three step
approach. In step 1 a total of 49 genes were selected as shown in
Table 1. These include (a) 19 ERT genes, previously reported to
be associated with decreased DNA methylation [12,13], (b) 4
genes which are not known to be ER-a target genes, but have been
demonstrated to be differently methylated depending on hormone
receptor status (DMHR) [12], (c) 20 PCGT genes, which play a
key role in stem cell biology and are more likely to have promoter
DNA hypermethylation in cancer [14,15,16] and (d) 6 genes
which are known to be methylated in breast cancer (MBC) [12]
and are not a member of the other three groups.
In step 2 we used MethyLight [17] to analyze the 49 genes
(Table 1; additional information see Table S1a–b) in peripheral
blood cell DNA of 83 healthy postmenopausal women (partici-
pating in UKOPS; see Materials and Methods) blinded for any
Table 1. Gene loci selected for the case/control study.
Gene group Gene loci Gene ID Accession # % methylated Gene group Gene loci Gene ID Accession # % methylated
(n=83) (n=83)
ERT BCL2 596 0 PCGT ITGA4 3676 0
MGA (II) 23269 0 CDKN2C 1031 0
NUP155 (II) 9631 1 TWIST1 7291 1
BRIP1 (II) 83990 6 SLC6A20* 54716 5
ZC3H4 (C19orf7) 23211 7 CYP1B1* 1545 11
MGA (I) 23269 11 NEUROG1* 4762 14
BRIP1 (I)* 83990 13 HOXA1* 3198 23
ESR1* 2099 33 TITF1* 7080 23
SIRT3* 23410 36 GDNF* 2668 24
NUP155 (I)* 9631 41 NEUROD1* 4760 31
PITX2 (II)* 5308 41 SFRP1* 6422 41
PITX2 (I)* 5308 42 MYOD1* 4654 59
DCC* 1630 46 CALCA 796 64
ZNF217 (II)* 7764 54 HOXA10 3206 64
FLJ39739* 388685 58 SFRP4 6424 69
PGR* 5241 77 ZBTB16 7704 71
TRIP10 9322 95 SLIT2 9353 72
ZNF217 (I) 7764 99 HIC1 3090 82
TFF1 7031 100 HOXA11 3207 82
MBC TERT 7015 0 SFRP5 6425 83
SYK* 6850 7
SEZ6L* 23544 45 DMHR TIMP3* 7078 12
GATA5 140628 61 CDH13* 1012 20
SFRP2 6423 76 HSD17B4* 3295 27
CCND2 894 82 PTGS2* 5743 77
Gene loci (either one locus or two separate loci of the same gene) have been analyzed and were selected based on their frequency of methylation in peripheral blood
cell DNA in the general population of 83 healthy postmenopausal women. Genes that were selected for further analysis in the case/control study are indicated with an
asterisk. ERT = estrogen receptor-a target; DMHR=differently methylated depending on hormone receptor status; PCGT = stem cell polycomb group target;
MBC=methylated in breast cancer.
doi:10.1371/journal.pone.0002656.t001
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history of cancer. DNA methylation at each locus (expressed as
percentage of methylated reference; PMR) was divided into
methylated (PMR.0) and unmethylated (PMR=0), given that
methylation was present only in a minority of women for most
genes. Based on the hypothesis that lack of methylation of ERT
(and DMHR) and methylation of PCGT genes predict breast
cancer risk, for further analysis in the case-control study (step 3),
we selected those ERT loci with a higher frequency in methylation
and those PCGT loci with a lower frequency of methylation in the
healthy postmenopausal women analyzed. All 4 DHMR and the 2
MBC gene loci with a lower frequency of methylation in the
healthy individuals were also selected for further analysis. On this
basis a total of 25 genes were further analyzed in a case-control
population (indicated with an asterisk in Table 1).
Step 3 involved conducting a carefully designed case-control
study involving 1,083 samples from both healthy women and
breast cancer patients provided from the ESTHER study (see
Material and Methods). 353 cases and 730 age-matched controls,
recruited in a state-wide study in Saarland, Germany, were
included in the study. Cases were more likely to have first-degree
relatives with breast cancer (odds ratio (OR) 1.90 (95% confidence
interval (CI) 1.27–2.85; P=0.002). In addition, there was a trend
towards increased breast cancer risk for women with late
menopause (50+ vs. ,50 yrs. OR 1.31 (95% CI 0.98–1.75;
P=0.10). There was no significant difference between cases and
controls regarding other features (Table 2). Results were essentially
unchanged when all continuous covariates were entered as such in
the model. A multiple logistic regression model based on the risk
factors addressed in table 2 showed a concordance statistic [18] of
0.585, which is identical with the concordance statistics demon-
strated for the Gail model [2]. Jointly, the various risk factors
contributed significantly to the prediction of disease status (P-value
for likelihood ratio test = 0.007, 12 degrees of freedom). Clinico-
pathological features of the cases are equivalent to an average
cohort of women with breast cancer (Table S2).
Using PMR values, 7 of the 25 genes analyzed in stage 3
demonstrated significant differences between the 353 cases and 730
controls (Table S3). 6 of these 7 genes retained their significant
differences after dividing each locus into methylated (PMR.0) or
unmethylated (PMR=0) and adjusting for age (Table 3). 5 of those
were significantly associated with breast cancer risk even after
adjusting for family history of breast cancer (Table 3), and after
additional control for all the other established breast cancer risk
factors (ZNF217: OR 1.48, 95% CI 1.12–1.97, P=0.006; NEU-
ROD1: OR 1.49, 95% CI 1.11–2.02, P=0.009; SFRP1: OR 1.44,
95% CI 1.07–1.92, P=0.015; TITF1: OR 1.49, 95% CI 1.02–2.18,
P=0.038; NUP155: OR 1.40, 95% CI 1.02–1.94, P=0.040). A
model solely based on the methylation markers of all 25 loci
Table 2. Breast cancer risk factors in cases and controls.
Characteristics Cases Controls OR*** 95% CI P-value
n % n % from to
Age (matching variable) 50–54 48 13.6 100 13.7
55–59 65 18.4 129 17.7
60–64 99 28.1 211 28.9
65–69 88 24.9 182 24.9
70–74 53 15.0 108 14.8
1st degree relative with breast cancer no 302 85.6 671 91.9 1.00
yes 51 14.4 59 8.1 1.90 1.27 2.85 0.002**
Age at menarche* ,12 29 8.9 85 12.5 1.00
12–13 132 40.6 264 38.8 1.45 0.91 2.31
14+ 164 50.5 331 48.7 1.44 0.88 2.36 0.39
Age at 1st childbirth* ,20 34 9.8 77 10.9 1.00
20–24 155 44.8 361 51.3 0.95 0.61 1.49
25–29 77 22.3 145 20.6 1.11 0.67 1.84
30+ 80 23.1 121 17.2 1.28 0.76 2.15 0.18
Age at menopause* ,50 172 52.3 403 58.8 1.00
50+ 157 47.7 283 41.2 1.31 0.98 1.75 0.10
BMI at age 20* ,18.5 61 17.9 101 15.1 1.00
18.52,22.5 190 55.7 369 55.3 0.88 0.61 1.28
22.5+ 90 26.4 197 29.5 0.86 0.54 1.23 0.34
Ever breastfed* no 148 42.5 263 36.9 1.00
yes 200 57.5 449 63.1 0.85 0.64 1.13 0.20
Ever use of hormone replacement therapy* no 152 46.8 348 50.4 1.00
yes 173 53.2 343 49.6 1.15 0.87 1.51 0.27
Cases (n = 353) and controls (n = 730) significantly differed regarding presence of 1st degree relatives with breast cancer. There was also a trend towards increased risk
for women with older age at first live birth and late menopause. *numbers do not add up to total numbers due to missing values for the following covariates (numbers
of missing values in cases/controls): age at menarche (28/50), age at 1st childbirth (7/26), age at menopause (24/44), BMI at age 20 (12/63), ever breastfed (5/18), ever
use of hormone replacement therapy (28/39); ** indicates P-values ,0.05; ***adjusted for other variables in table and taking care of missing values by multiple
imputation; OR = odds ratio; CI = confidence interval, BMI body mass index.
doi:10.1371/journal.pone.0002656.t002
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(methylated vs. unmethylated) showed a concordance statistic of
0.628. Jointly, the methylation status of the 25 genes was significantly
related to disease risk (P-value for likelihood ratio test with 25 degrees
of freedom=0.048). The combination of both risk factors and
methylation status increased the concordance statistic to 0.647. The
likelihood ratio test for adding traditional risk factors (family history,
age at menarche, age at 1st childbirth, age at menopause, BMI at age
20, history of breastfeeding, history of hormone replacement therapy,
7 degrees of freedom) to a model including methylation status of the
25 genes and the matching factor age yielded a P-value of 0.011.
Conversely, the likelihood ratio test for adding methylation status of
the 25 genes (25 degrees of freedom) to a model including traditional
risk factors yielded a P-value of 0.057.
Taken together, these patterns suggest exactly what we had
expected based on the selection of genes we used for this study: The
prediction of risk by traditional risk factors and methylation patterns
are not entirely independent. This again supports our hypothesis that
DNA methylation, on one hand may act as a surrogate for genetic
risk and lifelong environmental exposure, but on the other hand,
independently reflects the individual response of women to these
factors. In this context the results of the first genome-wide-breast
cancer susceptibility study which was recently reported are relevant.
The study identified 5 novel breast cancer susceptibility loci after a
three stage procedure, which started with analysis of 227,876 single
nucleotide polymorphisms (SNPs). The per allele odds ratio for an
association with breast cancer for the top five SNPs was between 1.07
and 1.26 [19]. This study suggests that it is unlikely that genetic tests
alone will achieve the sensitivity and specificity required for risk
assessment to guide preventive measures.
Furthermore, the two main histological subtypes in breast cancer
are invasive ductal and invasive lobular. It is known that there are
specific carcinogenic pathways for these two breast cancer groups.
There is growing evidence suggesting that a change in tumor tissue
architecture takes place in the genesis of invasive lobular breast
cancer known as epithelial-mesenchymal transition [20]. To study
whether this is also reflected in the epigenotype of peripheral blood
cells, we calculated separate ORs which predict each histological
subtype (Table S4a–b). The genes which predicted invasive ductal
breast cancer (ZNF217, NEUROD1, SFRP1) were completely
different from the genes associated with invasive lobular cancer
(PITX2, TITF1, GDNF, MYOD1, DCC). Interestingly genes which
predicted invasive lobular cancer are involved in diseases that affect
the mesenchyme like Hirschsprung disease or are known to be
involved in epithelial-mesenchymal transition [21–25].
Table 3. DNA methylation and odds ratios for breast cancer risk associated with lack of DNA methylation.
Gene
group Gene loci
Presence of methylation
in cases (all)
Presence of methylation
in controls Adjusted for age
Adjusted for age and family
history
OR (95% CI) P-value OR (95% CI) P-value
ERT BRIP1 (I) 31%(95/306) 30.5%(199/653) 0.97(0.72–1.31) 0.852 0.97(0.72–1.31) 0.85
ESR1 12.2%(39/320) 13.5%(91/676) 1.1(0.73–1.65) 0.645 1.09(0.73–1.64) 0.678
SIRT3 20.7%(61/294) 16.3%(102/627) 0.74(0.52–1.06) 0.1 0.74(0.52–1.06) 0.099
NUP155 (I) 21.9%(67/306) 28.6%(187/653) 1.42(1.03–1.96) 0.031* 1.4(1.02–1.94) 0.038*
PITX2 (I) 33.1%(106/320) 38%(257/676) 1.24(0.94–1.64) 0.133 1.23(0.92–1.63) 0.157
PITX2 (II) 48.1%(154/320) 48.5%(328/676) 1.01(0.78–1.33) 0.916 1.02(0.78–1.33) 0.913
DCC 35.1%(106/302) 41.7%(266/638) 1.32(0.99–1.75) 0.059 1.29(0.96–1.71) 0.086
ZNF217 (II) 39.4%(119/302) 48.9%(312/638) 1.49(1.13–1.97) 0.005* 1.49(1.12–1.97) 0.006*
FLJ39739 52%(153/294) 49.4%(310/627) 0.9(0.68–1.19) 0.474 0.9(0.68–1.19) 0.454
PGR 69.7%(223/320) 70.7%(478/676) 1.05(0.78–1.4) 0.754 1.04(0.77–1.39) 0.808
DMHR TIMP3 12.5%(40/320) 14.2%(96/676) 1.14(0.77–1.7) 0.511 1.13(0.76–1.69) 0.537
CDH13 13.8%(44/320) 15.4%(104/676) 1.15(0.78–1.68) 0.485 1.15(0.79–1.69) 0.462
HSD17B4 17.5%(56/320) 14.3%(97/676) 0.79(0.55–1.13) 0.19 0.78(0.55–1.13) 0.189
PTGS2 71.3%(228/320) 77.1%(521/676) 1.35(1–1.83) 0.049* 1.31(0.97–1.78) 0.078
PCGT SLC6A20 0.9%(3/320) 1.8%(12/676) 1.94(0.54–6.94) 0.307 2.2(0.61–7.96) 0.23
NEUROG1 4.3%(13/302) 4.7%(30/638) 1.1(0.56–2.14) 0.783 1.08(0.55–2.11) 0.822
HOXA1 11.1%(34/306) 13.9%(91/653) 1.28(0.84–1.96) 0.247 1.27(0.83–1.94) 0.272
TITF1 13.8%(44/320) 19.5%(132/676) 1.53(1.05–2.22) 0.025* 1.52(1.05–2.21) 0.028*
GDNF 14.7%(45/306) 18.7%(122/653) 1.32(0.91–1.92) 0.147 1.3(0.89–1.89) 0.176
NEUROD1 30.5%(91/298) 38.9%(250/642) 1.45(1.08–1.94) 0.014* 1.47(1.09–1.98) 0.011*
SFRP1 29.4%(94/320) 37.4%(253/676) 1.44(1.08–1.91) 0.014* 1.44(1.08–1.93) 0.013*
MYOD1 60%(192/320) 63.5%(429/676) 1.18(0.89–1.55) 0.244 1.17(0.89–1.54) 0.261
MBC SYK 2.2%(7/320) 2.4%(16/676) 1.07(0.43–2.62) 0.889 1.06(0.43–2.62) 0.9
CYP1B1 7.5%(24/320) 4.9%(33/676) 0.63(0.37–1.09) 0.096 0.62(0.36–1.08) 0.09
SEZ6L 50.3%(154/306) 52.8%(345/653) 1.1(0.84–1.45) 0.482 1.1(0.83–1.44) 0.517
6 genes analyzed showed differences in the methylation pattern between cases and controls when the data was adjusted for age; 5 remained significant even after
adjusting for age and family history of breast cancer. ERT = estrogen receptor-a target; DMHR=differently methylated depending on hormone receptor status;
PCGT = stem cell polycomb group target; MBC=methylated in breast cancer; * indicates P values ,0.05.
doi:10.1371/journal.pone.0002656.t003
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Beside histology, estrogen receptor status is the most important
feature in breast cancer. It is known that estrogen exposure (e.g.
serum estradiol in postmenopausal women) is only associated with
ER positive breast cancer [26]. Therefore we tested which of the
25 genes predict ER positive and which predict ER negative breast
cancer. Interestingly only the ERT gene loci (ZNF217 OR 1.48
(95% CI 1.01–2.16; P=0.042) and NUP155 OR 1.46 (95% CI
1.05–2.02; P=0.023) predicted ER positive breast cancer
(Table 4), whereas a PCGT gene locus (SFRP1 OR 2.37 (95%
CI 1.23–4.57; P=0.01) predicted ER negative breast cancer
(Table 5).
Given the relationship between ERT genes and breast cancer
risk we considered the possibility that current serum estrogen
activity may have an impact on DNA methylation of these genes.
To assess this possibility we analyzed ER-a bioactivity in the
serum of the cases and controls using a functional assay, which
measures the potential for binding to ER-a and transactivating the
estrogen responsive elements (EREs). This ER-a ERE-GFP (green
fluorescent protein) reporter test system in Saccharomyces cerevisiae
has been recently described [27,28]. Only peripheral blood cell
DNA methylation of ZNF217, one of the 10 ERT genes,
demonstrated a significant inverse correlation (r=20.112;
P=0.046) with ER-a bioactivity in the corresponding serum
(Figure 1). The possibility that this correlation could be triggered
by the current use of hormone replacement therapy was
considered. After excluding women currently taking hormone
replacement therapy, the inverse correlation remained significant
(r=20.166; P=0.013). Our data suggest that lack of ZNF217
methylation is a long-term surrogate marker of estrogen exposure,
indicating a woman’s risk of breast cancer. This observation fits
with evidence for changes in the activity of ZNF217 in breast
carcinogenesis. ZNF217 encodes a transcription factor which
mainly represses genes involved in differentiation [29]. Introduc-
tion of ZNF217 into human mammary epithelial cells leads to
immortalization [30]. In addition, ZNF217 is amplified and
overexpressed in 40% and 18% of breast cancer cell lines and
tissues, respectively [31,32].
Interestingly, analyzing solely women currently taking hormone
replacement therapy, PGR, which is also an ERT gene, was the
only locus demonstrating significant inverse correlation with
corresponding serum ER-a bioactivity (r=20.242; P=0.044).
Peripheral blood cell DNA methylation of PGR, the gene coding
Table 4. Odds ratios for estrogen receptor positive breast cancer risk associated with lack of DNA methylation.
Gene
group Gene loci
Presence of methylation
in cases (ER positive)
Presence of methylation
in controls Adjusted for age
Adjusted for age and family
history
OR (95% CI) P- value OR (95% CI) P- value
ERT BRIP1 (I) 30% (61/203) 30.5% (199/653) 1.01 (0.72–1.43) 0.943 1.01 (0.72–1.43) 0.942
ESR1 11.3% (24/212) 13.5% (91/676) 1.23 (0.76–1.99) 0.404 1.22 (0.75–1.98) 0.419
SIRT3 18.6% (36/194) 16.3% (102/627) 0.84 (0.55–1.27) 0.405 0.83 (0.54–1.27) 0.384
NUP155 (I) 21.2% (43/203) 28.6% (187/653) 1.48 (1.01–2.16) 0.042* 1.46 (1–2.13) 0.052
PITX2 (I) 32.5% (69/212) 38% (257/676) 1.27 (0.92–1.77) 0.151 1.25 (0.9–1.74) 0.189
PITX2 (II) 49.1% (104/212) 48.5% (328/676) 0.99 (0.73–1.35) 0.951 0.97 (0.71–1.33) 0.865
DCC 37.5% (75/200) 41.7% (266/638) 1.19 (0.86–1.66) 0.291 1.15 (0.82–1.6) 0.41
ZNF217 (II) 40% (80/200) 48.9% (312/638) 1.46 (1.05–2.02) 0.023* 1.44 (1.04–1.99) 0.029*
FLJ39739 52.6% (102/194) 49.4% (310/627) 0.88 (0.63–1.21) 0.43 0.87 (0.63–1.21) 0.413
PGR 69.3% (147/212) 70.7% (478/676) 1.07 (0.76–1.5) 0.69 1.05 (0.75–1.47) 0.789
DMHR TIMP3 11.3% (24/212) 14.2% (96/676) 1.27 (0.79–2.05) 0.327 1.26 (0.78–2.04) 0.347
CDH13 12.7% (27/212) 15.4% (104/676) 1.28 (0.81–2.01) 0.296 1.28 (0.81–2.03) 0.288
HSD17B4 17% (36/212) 14.3% (97/676) 0.81 (0.53–1.23) 0.323 0.8 (0.53–1.23) 0.31
PTGS2 72.2% (153/212) 77.1% (521/676) 1.31 (0.92–1.87) 0.129 1.26 (0.88–1.79) 0.205
PCGT SLC6A20 0.9% (2/212) 1.8% (12/676) 1.98 (0.44–8.92) 0.376 2.31 (0.5–10.61) 0.28
NEUROG1 5% (10/200) 4.7% (30/638) 0.91 (0.43–1.9) 0.794 0.89 (0.43–1.87) 0.762
HOXA1 11.3% (23/203) 13.9% (91/653) 1.26 (0.77–2.06) 0.349 1.25 (0.76–2.04) 0.378
TITF1 15.6% (33/212) 19.5% (132/676) 1.34 (0.88–2.04) 0.173 1.33 (0.87–2.02) 0.189
GDNF 15.8% (32/203) 18.7% (122/653) 1.23 (0.8–1.89) 0.339 1.2 (0.78–1.85) 0.406
NEUROD1 32% (63/197) 38.9% (250/642) 1.35 (0.96–1.9) 0.085 1.37 (0.97–1.94) 0.071
SFRP1 32.1% (68/212) 37.4% (253/676) 1.26 (0.91–1.76) 0.165 1.27 (0.91–1.77) 0.161
MYOD1 59% (125/212) 63.5% (429/676) 1.24 (0.91–1.71) 0.177 1.23 (0.89–1.69) 0.203
MBC SYK 2.8% (6/212) 2.4% (16/676) 0.82 (0.32–2.14) 0.691 0.82 (0.31–2.15) 0.688
CYP1B1 8% (17/212) 4.9% (33/676) 0.58 (0.31–1.06) 0.075 0.57 (0.31–1.06) 0.076
SEZ6L 50.2% (102/203) 52.8% (345/653) 1.11 (0.81–1.53) 0.514 1.1 (0.8–1.51) 0.569
Only the estrogen receptor regulated genes (NUP155 and ZNF217) predicted the estrogen receptor positive breast cancer, which fits with the general hypothesis that
estrogen exposure is associated to breast cancer risk. The data is adjusted for age alone or for age and family history of breast cancer.ERT = estrogen receptor-a target;
DMHR=differently methylated depending on hormone receptor status; PCGT = stem cell polycomb group target; MBC=methylated in breast cancer; ER = estrogen
receptor; OR = odds ratio; CI = confidence interval; * indicates P-values ,0.05.
doi:10.1371/journal.pone.0002656.t004
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for the progesterone receptor whose expression is strongly
regulated by ER-a, was not linked to breast cancer risk. PGR
methylation is not significantly different between non-neoplastic
breast tissue and breast cancer in premenopausal women [14], but
PGR methylation analyzed in breast cancer tissue adjusted for age
and expression of progesterone receptor is the most significant
predictor of ER status in breast cancer [12]. Using logistic
regression and after adjustment for age and progesterone receptor
status, lack of peripheral blood cell PGR methylation predicted the
ER status of the corresponding breast cancer (OR 1.52; 95% CI
1.10–2.11; P=0.012), whereas none of the other 24 gene loci’s
methylation status was an ER status predictor. This finding
indicates that the epigenetic pathways and interactions, which
have previously only been identified in cancer tissue, are also
reflected in peripheral blood, a source of DNA completely
unrelated to the breast cancer tissue.
The results did not however confirm the hypothesis that
peripheral blood cell DNA methylation of PCGT genes is
associated with an increased breast cancer risk. One possible
explanation for this could be that lack of methylation at specific
gene loci is only a surrogate for general global hypomethylation.
This hypothesis is supported by data demonstrating that lack of
folic acid supply (a condition leading to depletion of available
methyl groups and subsequent global hypomethylation) is
associated with some forms of cancer [33]. In order to study
global methylation we analyzed peripheral blood cell DNA
methylation of ALU repetitive elements, which has recently been
demonstrated to be an excellent marker for global methylation
[34]. None of the single predictive loci was associated with global
methylation in the 349 samples analyzed for methylation of ALU
(Table 6). ALU methylation did not differ between cases and
controls (controls (n=180), median PMR 54.8 and interquartile
range 34.0–84.0; cases (n=169), median PMR 51.1 and
interquartile range 34.7–73.0; Wilcoxon-Mann-Whitney test
P=0.25). This again indicates that the predictive potential of
DNA methylation is only reflected by specific gene loci rather than
by a surrogate marker which reflects global single-carbon
metabolism.
It is worth noting that the samples used in this study were
obtained after the diagnosis of breast cancer. In women with
metastatic breast cancer, tumor cells (5 tumor cells in 7.5 mL
blood) can be identified in the peripheral blood [35]. This means
Table 5. Odds ratios for estrogen receptor negative breast cancer risk associated with lack of DNA methylation.
Gene
group Gene loci
Presence of methylation
in cases (ER negative)
Presence of methylation
in controls Adjusted for age
Adjusted for age and family
history
OR (95% CI) P-value OR (95% CI) P- value
ERT BRIP1 (I) 31.6% (18/57) 30.5% (199/653) 0.95 (0.53–1.72) 0.875 0.95 (0.53–1.71) 0.866
ESR1 11.7% (7/60) 13.5% (91/676) 1.07 (0.47–2.43) 0.88 1.06 (0.47–2.43) 0.881
SIRT3 24.6% (14/57) 16.3% (102/627) 0.64 (0.34–1.22) 0.174 0.64 (0.34–1.23) 0.18
NUP155 (I) 21.1% (12/57) 28.6% (187/653) 1.51 (0.78–2.92) 0.224 1.51 (0.78–2.92) 0.225
PITX2 (I) 33.3% (20/60) 38% (257/676) 1.24 (0.7–2.18) 0.457 1.23 (0.7–2.17) 0.468
PITX2 (II) 46.7% (28/60) 48.5% (328/676) 1.04 (0.61–1.78) 0.873 1.04 (0.61–1.78) 0.876
DCC 29.8% (17/57) 41.7% (266/638) 1.67 (0.92–3.01) 0.091 1.66 (0.91–3) 0.096
ZNF217 (II) 36.8% (21/57) 48.9% (312/638) 1.59 (0.91–2.8) 0.106 1.61 (0.91–2.83) 0.1
FLJ39739 49.1% (28/57) 49.4% (310/627) 1.02 (0.59–1.77) 0.934 1.03 (0.59–1.78) 0.926
PGR 73.3% (44/60) 70.7% (478/676) 0.9 (0.49–1.64) 0.735 0.9 (0.49–1.64) 0.732
DMHR TIMP3 16.7% (10/60) 14.2% (96/676) 0.87 (0.42–1.79) 0.708 0.87 (0.42–1.79) 0.706
CDH13 15% (9/60) 15.4% (104/676) 1.03 (0.49–2.17) 0.933 1.03 (0.49–2.16) 0.941
HSD17B4 21.7% (13/60) 14.3% (97/676) 0.59 (0.31–1.14) 0.119 0.59 (0.31–1.14) 0.119
PTGS2 71.7% (43/60) 77.1% (521/676) 1.3 (0.72–2.36) 0.38 1.3 (0.72–2.35) 0.387
PCGT SLC6A20 0% (0/60) 1.8% (12/676)
NEUROG1 0% (0/57) 4.7% (30/638)
HOXA1 14% (8/57) 13.9% (91/653) 0.97 (0.44–2.14) 0.947 0.97 (0.44–2.12) 0.932
TITF1 8.3% (5/60) 19.5% (132/676) 2.53 (0.99–6.48) 0.053 2.53 (0.99–6.48) 0.053
GDNF 10.5% (6/57) 18.7% (122/653) 1.85 (0.77–4.43) 0.168 1.84 (0.77–4.4) 0.172
NEUROD1 28.1% (16/57) 38.9% (250/642) 1.66 (0.91–3.04) 0.098 1.66 (0.91–3.04) 0.099
SFRP1 20% (12/60) 37.4% (253/676) 2.37 (1.23–4.57) 0.01* 2.37 (1.23–4.57) 0.01*
MYOD1 65% (39/60) 63.5% (429/676) 0.94 (0.54–1.65) 0.839 0.94 (0.54–1.65) 0.828
MBC SYK 1.7% (1/60) 2.4% (16/676) 1.28 (0.16–9.91) 0.816 1.26 (0.16–9.79) 0.826
CYP1B1 6.7% (4/60) 4.9% (33/676) 0.71 (0.24–2.09) 0.529 0.71 (0.24–2.1) 0.534
SEZ6L 50.9% (29/57) 52.8% (345/653) 1.07 (0.62–1.85) 0.799 1.07 (0.62–1.84) 0.815
SFRP1, a polycomb group target gene unrelated to the hormonal exposure (estrogen), predicted the estrogen receptor negative breast cancer status. The data was
significant after adjusting for age alone or for age and family history of breast cancer. ERT = estrogen receptor-a target; DMHR=differently methylated depending on
hormone receptor status; PCGT = stem cell polycomb group target; MBC=methylated in breast cancer; ER = estrogen receptor; OR = odds ratio; CI = confidence interval;
* indicates P-values ,0.05.
doi:10.1371/journal.pone.0002656.t005
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that on average 1 out of 40 million cells in the peripheral blood of
women with metastatic (less in non-metastatic) are breast cancer
cells. Although MethyLight is very sensitive, this assay is only
capable of detecting methylated alleles in the presence of a 10,000
-fold excess of unmethylated alleles [17]. The possibility that the
methylation signal we detect in peripheral blood cell DNA is
influenced by tumor cell DNA can therefore be discounted.
In this first large scale epigenotyping study, we were able to
demonstrate that particular DNA methylation patterns in
peripheral blood may serve as a surrogate marker for breast
cancer risk. The current report also provides a basis for further
research to assess the role of a combination of genotyping and
epigenotyping as a clinical tool to predict an individual’s risk of
developing breast cancer, other cancers and chronic diseases with
sufficient accuracy to guide preventive measures.
Materials and Methods
Samples
UKOPS (United Kingdom Ovarian Cancer Population Study)
study is being carried out in 10 regional centers in England, Wales
and Northern Ireland. Recruitment has started since January 2006
and is aiming to include 2,000 ovarian cancer patients, 1,500
benign and 5,000 controls. Recruitment of cancer cases has been
carried out during visits to the Gynecological Oncology wards.
Control participants have been recruited from the UKCTOCS
(United Kingdom Collaborative Trial of Ovarian Cancer
Screening) trial centers (www.ukctocs.org.uk). Detailed informa-
tion about the medical history was obtained by a standardized
questionnaire. Diagnosis data from histology and cytology reports
has also been included. Furthermore, serum and whole blood were
collected from all subjects. Written consent was obtained from
each participant. Ethical approval was received by the joint
University College London Committees on the Ethics of Human
Research (Committee A). In the current study 83 healthy
postmenopausal women (blinded for cancer history) were selected
for step 2.
ESTHER (www.esther.dkfz.org/esther/) is a population-based
study carried out in the state of Saarland (located in South West
Germany). In the clinical arm of the study, 1,981 cancer patients
age 50 to 75, including 380 women with breast cancer, were
recruited during their first stay in the hospital for primary cancer
treatment. In the community arm, of the study, 9,953 women and
men age 50–75 were recruited during routine health examinations
by their general practitioners. Recruitment and baseline exami-
nations were carried out in 2000–2003. In both study arms,
detailed information about medical history, including family
history, sociodemographic and lifestyle factors and current health
status was obtained by standardized questionnaire. In addition,
serum and whole blood samples were collected. Written informed
consent was obtained from all subjects. The protocol was
approved by the Ethics Committee of the Medical Faculty of the
University of Heidelberg. Germany. In this study, all 353 cases
Figure 1. Association of ER-a bioactivity of serum with DNA
methylation of ZNF217 in the corresponding peripheral blood
cell DNA. Peripheral blood cell DNA methylation of ZNF217, one of the
estrogen receptor target genes studied, demonstrated a significant
inverse correlation with ER-a bioactivity in the corresponding serum
(r=20.112; P= 0.046).
doi:10.1371/journal.pone.0002656.g001
Table 6. Correlation of global methylation (ALU repetitive
elements) with methylation at single gene loci.
Gene
group Gene loci
Cases &
Controls Cases only Controls only
n=349 n=169 n=180
rho P-value rho P-value rho P-value
ERT BRIP1 (I) 0.037 0.501 0.035 0.657 0.047 0.543
ESR1 0.125 0.0204* 0.162 0.0361* 0.105 0.164
SIRT3 0.062 0.272 0.001 0.987 0.115 0.142
NUP155 (I) 0.004 0.946 0.031 0.692 20.026 0.732
PITX2 (I) 0.017 0.752 0.031 0.691 0.006 0.938
PITX2 (II) 0.019 0.720 20.087 0.263 0.120 0.111
DCC 0.040 0.477 0.026 0.740 0.054 0.493
ZNF217 (II) 0.023 0.681 20.012 0.880 0.041 0.601
FLJ39739 20.048 0.395 20.080 0.319 20.012 0.875
PGR 20.061 0.255 20.149 0.055 0.014 0.851
DMHR TIMP3 0.028 0.780 20.023 0.772 0.058 0.441
CDH13 20.060 0.267 0.045 0.560 20.146 0.052
HSD17B4 0.012 0.828 0.115 0.138 20.095 0.206
PTGS2 0.094 0.082 0.119 0.126 0.070 0.356
PCGT SLC6A20 20.030 0.578 20.063 0.416 20.006 0.937
NEUROG1 0.062 0.261 0.034 0.692 0.109 0.162
HOXA1 20.049 0.373 0.042 0.598 20.131 0.087
TITF1 20.015 0.780 20.019 0.804 20.011 0.884
GDNF 20.029 0.599 20.051 0.518 20.020 0.799
NEUROD1 0.037 0.509 0.064 0.423 0.001 0.986
SFRP1 20.046 0.396 20.148 0.056 0.045 0.553
MYOD1 0.043 0.431 20.026 0.742 0.099 0.189
MBC SYK 0.007 0.901 0.057 0.465 20.031 0.682
CYP1B1 0.074 0.267 0.080 0.306 0.068 0.364
SEZ6L 20.129 0.018*20.167 0.034* 20.093
0.227
Analysis of ALU methylation in a subset of cases (n = 169) and controls (n = 180)
demonstrated no significant association with the predictive loci (NUP155,
ZNF217, PTGS2, TITF1, NEUROD1, SFRP1), supporting the role of DNA
methylation at particular loci as a valuable predictive marker for breast cancer
risk.ERT = estrogen receptor-a target; DMHR=differently methylated depending
on hormone receptor status; PCGT = stem cell polycomb group target;
MBC=methylated in breast cancer; * indicates P-values ,0.05.
doi:10.1371/journal.pone.0002656.t006
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with postmenopausal invasive breast cancer were included, and a
stratified random subset of 730 age-matched postmenopausal
women were selected as controls.
DNA isolation and storage of DNA
A standard chloroform-based DNA isolation protocol has been
used to extract DNA from whole blood from the UKOPS samples.
DNA was extracted from whole blood samples of the ESTHER
study participants by Invisorb extraction kits (Invitek; www.invitek.
de). DNA from both sample collections have been dissolved in
distilled water and stored at 280uC until analysis.
Analysis of DNA Methylation
Sodium bisulfite conversion (Zymo Research; www.zymoresearch.
com), MethyLight analysis (Applied Biosystems; www.
appliedbiosystems.com) and nucleotide sequences for most
MethyLight primers and probes in the promoter or 59 end
region was described recently [12,14,34,36]. Each Methy-
Light reaction at a specific locus covers on average 5–7 CpG
dinucleotides. A detailed list of primer and probes (Meta-
bion; www.metabion.com) for all analyzed loci is provided in
Table S1. Briefly two sets of primers and probes, designed
specifically for bisulfite-converted DNA, have been used: a
methylated set for the gene of interest and a reference set
(COL2A1) to normalize for input DNA. Specificity of the
reactions for methylated DNA was confirmed separately
using SssI (New England Biolabs; www.newenglandbiolabs.
co.uk) treated human white blood cell DNA (heavily
methylated). The percentage of fully methylated molecules
at a specific locus were calculated by dividing the GENE:-
COL2A1 ratio of a sample by the GENE:COL2A1 ratio of the
SssI-treated human white blood cell DNA and multiplied by
100. The abbreviation PMR (Percentage of Methylated
Reference) indicates this measurement.
The analysis was performed blinded and cases and controls were
randomly mixed for bisulfite treatment and real-time PCR. The
concentration of bisulfite modified DNA (assessed by the level of the
reference gene COL2A1) was the same between cases and controls.
ER-a serum bioactivity assay
ER-a bioactivity has been as recently described [27]. Each
serum has been tested blindly in quadruplicates (20 mL for each
reaction in a total of 100 mL) and a mean value has been
calculated based on four independent measures (done on two
different days).
Statistical Analysis
Descriptive analyses were performed on age and known risk
factors for breast cancer among cases and controls and on clinical
features among breast cancer cases. Percent methylated, mean and
median values of PMR were calculated for the selected gene loci.
Differences in PMR values between cases and controls were
analyzed by means of Wilcoxon-Mann-Whitney test. In addition,
odds ratios for breast cancer (overall and according to estrogen
receptor status) associated with absence of methylation, adjusted
for age (matching factor) and for positive family history (at least
one first degree relative with breast cancer) as well as for other
established breast cancer risk factors were calculated by multiple
logistic regression. Multiple imputation was employed to deal with
missing covariate data in multivariable analyses. Initially, a linear
term for percent methylation in addition to the dichotomous term
for absence of methylation was included in the models to address a
potential dose-response relationship. As this term did not
significantly improve prediction for any of the 25 genes assessed,
it was dropped from the final models. Joint contribution of
methylation status of all 25 genes to the prediction of breast cancer
risk was evaluated by concordance statistics [18] and likelihood
ratio tests. Spearman’s rho was calculated to assess the correlation
of global methylation (ALU repetitive elements) with methylation
at single gene loci. All statistical analyses were done using SAS
Software, version 8.2.
Supporting Information
Table S1 Information on genes analyzed. S1A: Primers and
probe sequences for MethyLight. S1B: General gene information.
Gene alternative names, chromosomal location and amplicons’
position relative to the transcription start site are indicated.
Found at: doi:10.1371/journal.pone.0002656.s001 (0.14 MB
DOC)
Table S2 Clinicopathological characteristics of breast cancer
cases used for the study. UICC=Union internationale contre le
cancer; *Among those with information; n/a= not applicable.
Found at: doi:10.1371/journal.pone.0002656.s002 (0.05 MB
DOC)
Table S3 Mean and median percentage of methylated reference
(PMR) value of the 25 different loci. 7 genes of those analyzed
demonstrated significant differences in the level of methylation
between cases and controls, based on the quantitative results on
peripheral blood cell DNA. ERT= estrogen receptor-a target;
DMHR=differently methylated depending on hormone receptor
status; PCGT= stem cell polycomb group target; MBC=methy-
lated in breast cancer; * indicates P-values ,0.05
Found at: doi:10.1371/journal.pone.0002656.s003 (0.08 MB
DOC)
Table S4 Odds ratios for invasive ductal and lobular breast
cancer risk associated with peripheral blood DNA methylation.
S4A: Risk for invasive ductal breast cancer. S4B: Risk for invasive
lobular breast cancer.
Found at: doi:10.1371/journal.pone.0002656.s004 (0.14 MB
DOC)
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